Camurus

Kvinna i laboratorium bär ansiktsmask och skyddsglasögon, visar säkerhet och noggrant laboratoriearbete.

CEO: Fredrik Tiberg

Investment area: Quality of life

Investment year: 1991

Website: www.camurus.com

Camurus develops and commercializes innovative, long-acting medicines for patients with severe and chronic diseases, such as addiction, pain, cancer, and endocrine disorders. Through its FluidCrystal® technology, medicines are released in a controlled manner in the body, providing long-lasting therapeutic effects. Camurus aims to create value for patients, healthcare providers, and society. Headquartered in Lund, Camurus operates across Europe, the US, and Australia. Its stock (CAMX) is listed on Nasdaq Stockholm.